# TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) · Edgar & Edgarette company card

> Teva Pharmaceutical Industries Limited (TEVA) grew revenue 4.3% in FY2025 to $17.3 billion, operating margin 12.5% against a -3.8% median for pharmaceutical preparations, equity 19.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 818686 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/TEVA) · [JSON](https://www.pops4.com/boards/company/TEVA.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $17.3B |
| Revenue growth, 1 year | 4.3% |
| Revenue growth per year | 2.1% |
| Operating margin | 12.5% (prior year -1.8%) |
| Net margin | 8.2% |
| Operating cash flow | $1.6B |
| Capital spending | $501M |
| Free cash flow | $1.1B |
| Cash | $3.6B |
| Long-term debt | — |
| Total assets | $40.7B |
| Total equity | $7.9B |
| Equity ÷ assets | 19.4% |
| Return on equity | 17.9% |
| Dividend per share | $0 |
| Dividend years rising | 0 |

## Readings, computed from those figures

- Altman Z: -0.41 (distress zone)
- Piotroski F: 8 of 9 (strong)
- Beneish M: -2.37 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $17.3B (FY2025). Experience: revenue up 4.3% on the year, up 2.1% a year over 4 years; operating margin 12.5%, up from -1.8%. Soundness: equity 19.4% of assets, return on equity 17.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $16.1B and $19.0B next year (method v4.1: its own 4-year record of growth weighed at 50% against $10B+ filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $14.9B to $20.3B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 12.5% against a -3.8% median; growth 4.3% against 13.7%.

Range logged 2026-09-24, receipt 3fe92e6e84ad0296, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-10-29 ([filing](https://www.sec.gov/Archives/edgar/data/818686/000119312526438019/0001193125-26-438019-index.htm))

## Recent filings

- 10-Q · filed 2026-11-03 · [filing](https://www.sec.gov/Archives/edgar/data/818686/000081868626000006/0000818686-26-000006-index.htm)
- 8-K · filed 2026-11-03 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/818686/000117184326007054/0001171843-26-007054-index.htm)
- 8-K · filed 2026-10-29 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/818686/000119312526438019/0001193125-26-438019-index.htm)
- 8-K · filed 2026-09-16 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/818686/000119312526393116/0001193125-26-393116-index.htm)
- 8-K · filed 2026-09-14 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/818686/000119312526390562/0001193125-26-390562-index.htm)
- 8-K · filed 2026-09-11 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/818686/000119312526389264/0001193125-26-389264-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000818686.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=818686

## Cite

POPS4, Edgar & Edgarette: TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/TEVA. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.